Article Sidebar

PDF
Date Published: 10/03/2021
Abstract Views: 222
Views PDF: 205
DOI: https://doi.org/10.51298/vmj.v498i1.21
Issue
Vol. 498 No. 1 (2021)
Section
Các bài báo
How to Cite
Anh Sơn, H., Mạnh Cường, L., & Văn Chuyên, N. (2021). EVALUATION THE LATE APOPTOSIS EFFECTS OF VACCINE-STRAIN MEASLES VIRUS AND NIMOTUZUMAB ON CANCER CELLS. Vietnam Medical Journal, 498(1). https://doi.org/10.51298/vmj.v498i1.21

EVALUATION THE LATE APOPTOSIS EFFECTS OF VACCINE-STRAIN MEASLES VIRUS AND NIMOTUZUMAB ON CANCER CELLS

Hồ Anh Sơn1,, Lê Mạnh Cường2, Nguyễn Văn Chuyên1
1 Học viện Quân y
2 Bệnh viện YHCT Trung ương

Main Article Content

Abstract

Objectives: This study aims to evaluate of late apoptosis effects of vacine-strain measles virus (MeV) and Nimotuzumab against cancer cells. Materials and methods: MeV and Ninotuzumab were used to induce late apoptosis pathway on Hep2 cancer cells. Hep2 cells treated with MeV and Nimotuzumab were collected at 48, 72 hours and 96 hours to perform flow cytometry. Results: The proportion of late apoptosis cells in treated groups was significantly higher than control group. MeV and Nimotuzumab combination induced higher rate of late apoptosis cells than thouse in single treatment groups. Conclusion: MeV and Nimotuzumab combination increases late apoptosis on head and neck cancer Hep2 cells than single MeV or Nimotuzumab treatment.

Article Details

Keywords

Head and neck squamous-cell carcinoma, measles virus vaccine, Nimotuzumab, apoptosis.

References

1. Vigneswaran N., Williams M.D. (2014). Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac Surg Clin North Am., 26(2):123-141.
2. Prestwich R.J., Harrington K.J., Pandha H.S., et al. (2008). Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther., 8(10):1581-1588.
3. Miyamoto S., Inoue H., Nakamura T., et al. (2012). Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res., 72(10): 2609-2621.
4. Msaouel P., Opyrchal M., Domingo Musibay E., et al. (2013). Oncolytic measles virus strains as novel anticancer agents. Expert Opin Biol Ther., 13(4):483-502.
5. Ong H.T., Timm M.M., Greipp P.R., et al. (2006). Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp Hematol., 34(6):713-720.